← All candidates
14 insider buys in the last year — $70.4K in all.
51 filings on record.
PCSAProcessa Pharmaceuticals, Inc.
NasdaqCM · Healthcare · $5.17M
$1.85
-5.47% · Sep 16
14 insider buys in the last year — $70.4K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 14 buys◆ 2 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 4×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what PCSA ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$5.17M
Float
2.5M
90% public
Short % float
Pro
Price / profit
2.9
Price / future profit
—
Price / sales
—
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Financial Officer
Skibsted Russell
Bought $6.3K on Jun 30 — 3,277 sh @ $1.93, held direct, 20% of their stake.
No completed positions to measure
Chief Executive Officer
Ng George K
Bought $5.9K on Jul 1 — 3,057 sh @ $1.93, held direct, 20% of their stake.
No completed positions to measure
Chief Administrative Officer
Guy Wendy
Bought $4.7K on Jun 15 — 2,118 sh @ $2.22, held direct, 18% of their stake.
No completed positions to measure
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
16 more transactions on Pro →Context
Earnings · EPS vs forecast
3 of 4 quarters beat
Q3 '25−$1.75 act+$0.25
Q2 '25−$6.25 act−$0.50
Q1 '25−$7.50 act+$11.75
Q4 '24−$18.50 act+$4.50
Coverage
Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?Simply Wall St. · 12-17Insider Stock Buyers At Processa Pharmaceuticals Recouped Some Losses This WeekSimply Wall St. · 08-06Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio ProgressInsider Monkey · 07-11Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims DeclineMT Newswires · 12-18
The file stays open
51 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice